Safety and efficacy of high-dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus

Journal of the Pediatric Infectious Diseases Society

Volumn 3, Issue 4, 2014, Pages 294-303

  Dougherty, Kelly A ^a   Schall, Joan I ^b   Zemel, Babette S ^a   Tuluc, Florin ^a   Hou, Xiaoling ^a   Rutstein, Richard M ^a   Stallings, Virginia A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

HIV; Nutrition; Pediatrics; Supplementation; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; RNA;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VITAMIN SUPPLEMENTATION; YOUNG ADULT;

EID: 84930158287     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu012     Document Type: Article

References (36)

1. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics 2009; 123:e121-6.
2. Stephensen CB, Marquis GS, Kruzich LA, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006; 83:1135-41.
3. Rutstein R, Downes A, Zemel B, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr 2011; 30:624-8.
4. Eckard AR, Judd SE, Ziegler TR, et al. Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther 2012; 17:1069-78.
5. Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis 1994; 169:889-93.
6. Kim JH, Gandhi V, Psevdos G Jr, et al. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses 2012; 28:235-41.
7. Viard JP, Souberbielle JC, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25:1305-15.
8. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008; 4:80-90.
9. Bang U, Kolte L, Hitz M, et al. Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials 2012; 13:162-70.
10. Bearden A, Abad C, Gangnon R, et al. Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. J Clin Endocrinol Metab 2013; 98:1726-33.
11. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev 2008; 66:S178-81.
12. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitaminD sufficiency: implications for establishing a neweffective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317-22.
13. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22:142-6.
14. Heaney RP. Vitamin D endocrine physiology. J Bone Miner Res 2007; 22 (Suppl 2):V25-7.
15. Garland CF, French CB, Baggerly LL, Heaney RP. Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. Anticancer Res 2011; 31:607-11.
16. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85:6-18.
17. Vieth R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml). Best Pract Res Clin Endocrinol Metab 2011; 25:681-91.
18. Dougherty KA, Schall JI, Rovner AJ, et al. Attenuated maximal muscle strength and peak power in children with sickle cell disease. J Pediatr Hematol Oncol 2011; 33:93-7.
19. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 1980; 9:271-80.
20. Schall JI, Semeao EJ, Stallings VA, Zemel BS. Self-assessment of sexual maturity status in children with Crohn's disease. J Pediatr 2002; 141:223-9.
21. National Research Council. Dietary reference intakes for calcium and vitamin D.Washington, D.C: The National Academies Press; 2011.
22. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011; 6:1609-16.
23. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004; 190:271-9.
24. Caldwell MB, Oxtoby MJ, Simonds RJ, et al. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43(RR-12):1-10.
25. Castro KG,Ward JW, Slutsker L, et al. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41 (RR-17):1-15.
26. Kakalia S, Sochett EB, Stephens D, et al. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr 2011; 159:951-7.
27. Giacomet V, Vigano A, Manfredini V, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials 2013; 14:51-60.
28. Meyzer C, Frange P, Chappuy H, et al. Vitamin D deficiency and insufficiency in HIV infected children and young adults. Pediatr Infect Dis J 2013; 32:1240-4.
29. Steenhoff AP, Redwood A, Pettifor JM, et al. Vitamin D status in HIV-infected patients with and without tuberculosis: a pilot study. J Acquir Immune Defic Syndr 2012; 61:e21-3.
30. Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr 2012; 95:678-85.
31. 3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab 2012; 97:4004-13.
32. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008; 87:1952-8.
33. 3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73:288-94.
34. 3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 54:1013-25.
35. Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapynaive and successfully treated Swiss HIV patients. AIDS 2010; 24:1127-34.
36. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-8.